Please login to the form below

Not currently logged in
Email:
Password:

Immunocore names CEO

Eliot Forster is chairman of the MedCity project
Immunocore Eliot Forster

The UK-based biotech Immunocore has appointed industry veteran Dr Eliot Forster as CEO.

Dr Forster will lead the firm, which is focused on the development of biological drugs to treat cancer and viral diseases and has several partnerships in place with major pharma companies including Genentech, GlaxoSmithKline and AstraZeneca.

He joins from his role as CEO of Creablis, a UK biotech with a focus on dermatology and pain management, and he also holds the role of chairman of the UK's MedCity project to grow a life sciences cluster in south east England.

“I am delighted to welcome Eliot Forster to Immunocore, and as a member of the Board,” said Dr Jonathan Knowles, executive chairman of the company. “His significant drug development experience will be invaluable to Immunocore as we continue to deliver within our partnerships and advance our proprietary ImmTAC pipeline."

Dr Forster's experience includes role at the pharma major Pfizer where he served as head of development and operations for its operations in the EU and Pfizer. During this time he helped bring several drugs to markets including Celebrex (celecoxib) and Relpax (eletriptan) and to establish the company in India and China.

13th January 2015

From: Research

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Main image2
Customers, content and change
By Dominic Tyer...
Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...